Epidemiology of new-onset paroxysmal atrial fibrillation in the General Intensive Care Unit population and after discharge from ICU. A retrospective epidemiological study

Leonid Koyfman, Evgeni Brotfain, Ruslan Kutz, Amit Frenkel, Andrei Schwartz, Avi Boniel, Alexander Zlotnik, Moti Klein

Department of Anesthesiology and Critical Care, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel

Abstract

Background: Evidence of various cardiac arrhythmias in septic patients has been demonstrated by multiple clinical reports and observations. Most cardiac arrhythmias in sepsis are new-onset and may be related to sepsis-induced myocardial dysfunction. We propose to investigate and analyze data of new-onset paroxysmal atrial fibrillation (AF) in a critically ill septic population.

Methods: This is a retrospective epidemiologic study. We collected clinical data from two hundred septic patients who developed a new episode of atrial fibrillation during their hospitalization in General Intensive Care Unit (GICU) between January 2007 and June 2013.

Results: Of these 200 septic patients, 81 septic patients developed a new episode of AF and included in the present study. Thirty-seven patients had no past medical history of atrial fibrillation (AF) or antiarrhythmic therapy (new episode of atrial fibrillation, Group 1) and 44 had previously known episodes of atrial fibrillation and were prescribed antiarrhythmic therapy at home (Group 2). Group 2 patients had longer duration of recurrent episodes of atrial fibrillation compared to patients in Group 1 (11.07 ± 8.7 vs. 7.4 ± 6.1 days; \( P = 0.013 \)). The overall ICU and in-hospital mortality rate was similar in both study groups. There was no significant difference in new stroke and pulmonary embolism (PE) between both study groups (\( P > 0.05 \)).

Conclusion: In the present study we demonstrated no difference in morbidity and mortality rate in-ICU and after discharge between septic patients who had previous AF episodes and patients who had no previous past medical history of any cardiac arrhythmias.

Key words: cardiac arrhythmias, new-onset atrial fibrillation; intensive care, sepsis

Sepsis is one of the most important causes of morbidity and mortality in critically ill patients worldwide [1−3]. Progressive cardiovascular deterioration plays a central role in the pathogenesis of sepsis [4−7]. Evidence of various cardiac arrhythmias in septic patients has been demonstrated by multiple clinical reports and observations [8−11]. Most cardiac arrhythmias in sepsis are new-onset and may be related to sepsis-induced myocardial dysfunction, autonomic dysfunction and, most likely also, by impairment and involvement of the cardiac conduction system [9−13]. However, abnormalities of the cardiac conduction system in sepsis have not been well described so far [6]. Both sepsis-induced myocardial dysfunction and sepsis-induced cardiac arrhythmias are related to high intensive care unit (ICU) mortality and increased risk of acute stroke [11, 14, 15]. Subsequently, optimal management with the goal of restoring normal cardiac rhythm and function (antiarrhythmic drugs, inotropic agents, mechanical ventilation etc.) is needed.

The clinical significance of recurrent acute atrial fibrillation (AF) in septic patients with preexisting cardiac comor-
bidities, which can be complicated and triggered by severe systemic inflammatory reaction [9–11] is poorly understood. Some authors [16] have shown a higher frequency of recurrent AF episodes in patients with preexisting cardiac arrhythmias than in patients with unknown past cardiac history during sepsis. One might argue that the prognostic impact of previously known cardiac arrhythmias, as a sign of chronic underlying cardiovascular disease, is worst in the septic population. However, no studies focusing on septic patients’ outcome after recurrent AFs with underlying cardiac disease have been done yet.

We investigate and analyzed data and clinical outcome of new-onset paroxysmal atrial fibrillation in a critically ill septic population with unknown (Group 1) and preexisting medical history of atrial fibrillation (Group 2), treated with antiarrhythmic therapy while hospitalized in our General ICU (GICU) and after the discharge from hospital during the last 6 years.

METHODS
The Human Research and Ethics Committee at Soroka Medical Center in Beer-Sheva, Israel approved this study (RN: SOR-0043-14). We collected clinical data from all cases of septic patients who developed a new episode of atrial fibrillation during their hospitalization in General Intensive Care Unit, Soroka Medical Center between January 2007 and June 2013. In this study, all clinical data was extracted from the MetaVision™ Clinical Information System for ICUs (IMDsoft®, Israel) and the OFEK Electronic Data system (in-hospital medical record electronic system). This is an observational, retrospective study performed in a university teaching hospital.

INCLUSION CRITERIA
All critically ill septic persons who developed an episode of paroxysmal atrial fibrillation during the ICU stay and had documented sinus rhythm before admission to the ICU.

EXCLUSION CRITERIA
Critically ill septic patients who had persistent episodes of paroxysmal atrial fibrillation and patients who had stayed in the ICU less than 48 hours were excluded from the present study.

VARIABLES, MEASURES, PRIMARY AND SECONDARY OUTCOME
Data collected includes the demographic data, cause of sepsis on admission, APACHE-II (Acute Physiology and Chronic Health Evaluation II) and SOFA (The Sequential Organ Failure Assessment score) scores, patients’ cardiac comorbidities (myocardial infarction (MI) in the past, chronic AF, cardiomyopathy) and length of ICU stay, epidemiologic data of new episode of atrial fibrillation (total duration of arrhythmia, time of incident, type of antiarrhythmic therapy); and laboratory data (phosphate, calcium, magnesium, potassium, glucose blood levels; urea, creatinine blood levels; hemoglobin, platelets, white blood cell count, pH arterial blood; results of microbiological studies). All laboratory data was collected during the new and recurrent AF episode within ICU stay. Moreover, in-ICU and in-hospital mortality rates were collected. The primary outcome endpoint of the present study was the ICU mortality rate while secondary outcomes were complications of new arrhythmic episode (incidence of new stroke (CVA) and pulmonary embolism (PE)) during and after ICU stay.

STATISTICAL ANALYSIS
Data summaries were performed using SPSS v. 17 (SPSS, Chicago, USA). Data collected in this study were summarized using frequency tables, summary statistics, confidence intervals, and P-values as appropriate. For continuous variables with non-normal distribution, comparisons were evaluated for significance with the use of the Wilcoxon rank-sum test. For categorical variables, proportions were compared using Fisher’s exact test or χ² as appropriate. Continuous variables were analyzed with a Student’s t-test or the Wilcoxon rank sum test, depending on the validity of the normality assumption. A two-tailed P-value < 0.05 was considered to be significant.

RESULTS
In total, 200 septic critically ill patients were hospitalized in the GICU over the above-mentioned six-year period. Of these, 81 septic patients with an atrial fibrillation episode were included in the present study (Table 1). Thirty-seven patients had no past medical history of atrial fibrillation or antiarrhythmic therapy (new episode of atrial fibrillation, Group 1, see Table 1) and 44 had previously known episodes of atrial fibrillation and were prescribed antiarrhythmic therapy at home (recurrent episode of atrial fibrillation, Group 2, Table 1). Demographic data showed an older age of Group 2 patients, P = 0.04; Table 1). There was a higher incidence of line and wound sepsis in Group 1 patients compared to a higher incidence of intrabdominal sepsis in Group 2 (P < 0.03, Table 2). There was no significant difference in length of ICU and hospital stay, APACHE II and SOFA scores and continuous renal replacement therapy (CRRT) requirements.

The overall ICU and in-hospital mortality rate was similar in both study groups (Table 1). Group 2 patients had longer duration of recurrent episodes of atrial fibrillation compared to patients in Group 1 (11.07 ± 8.7 vs. 7.4 ± 6.1 days; P = 0.013, Table 2). Subsequently, the duration of antiarrhythmic therapy during hospital stay and at home after an arrhythmic episode was significantly longer in Group 2 critically
ill patients ($P < 0.05$, see Table 2). Group 2 patients were more likely to receive anticoagulation therapy during their hospital stay, and at home, than Group 1 ($P < 0.05$, Table 2). However, there was no significant difference in new stroke and pulmonary embolism (PE) between both study groups ($P < 0.05$, Table 2).

There were no significant differences in laboratory data between both study groups during the new and recurrent AF episodes in the ICU stay (see Table 3).

**DISCUSSION**

Atrial fibrillation (AF) is one of the most widespread cardiac arrhythmias in the critically ill septic population [14–19]. AF in septic patients is very poorly characterized compared to the dysfunction of other major organs [20–24] and is believed to be multifactorial [25–29]. A number of previously published studies have shown a strong clinical relationship between severity of the illness (sepsis), episodes of new acute atrial fibrillation and worst clinical outcome [30–32]. Even more, it has been shown that new atrial fibrillation in the septic ICU population is associated with an increased risk of acute stroke and prolonged ICU duration [14, 15, 30–32].

Our data did not find a significant difference in clinical outcome (in-ICU and in-hospital mortality; new embolic events (CVA or PE)) in septic patients with new onset AF episodes with no past medical history of atrial fibrillation or antiarrhythmic therapy and septic persons who had pre-existing cardiac disease: previously known coronary artery disease (old MIs) ($n = 20$), idiopathic cardiomyopathy ($n = 5$) and chronic atrial fibrillation only ($n = 19$). Also patients with coronary artery disease and idiopathic cardiomyopathy had well-documented episodes of AF in the past. NS — non significant, other abbreviations explained in text.
ously known episodes of atrial fibrillation and prescribed antiarrhythmic therapy at home. Moreover, some patients also had preexisting coronary artery disease and idiopathic cardiomyopathy history (Group 2). These findings correlated well with previously published data. Thus, Walkey et al. [16, 33] demonstrated that only a small number of risk factors (right heart catheterization, diagnosis of endocarditis and past coronary artery bypass graft surgery) are associated with an increased risk of new atrial fibrillation episodes in septic ICU patients. Other cardiovascular comorbidities (heart failure, hypertension, previous myocardial dysfunction, valve disease) had no correlation with new AF episodes.

Kanji et al. [34] documented the clinical follow up of 139 patients with new onset AF and 186 patients with preexisting AF in a mixed ICU population. Pharmacological and electrical rhythm conversions were more successful in new-onset AF patients in comparison to the preexisting AF population [34]. The mortality rate in ICU and after discharge from the intensive care unit was similar for both groups (22–27% and 32–38% respectively). Our data supported their findings, but considered only the septic population of the ICU. In our study, the mortality rate in ICU and after discharge was 37% and 21% for patients with new onset AF compared to 38% and 23% for septic patients with preexisting AF. We found significantly longer duration of antiarrhythmic therapy in hospital and at home for patients with preexisting AF than with new onset AF. Appropriate recommendations of anticoagulation therapy for elderly septic patients with new onset AF still remain indeterminate [35]. In the same study, Kanji et al. [34] found similar rates of therapeutic anticoagulation for new onset and preexisting AF (16% and 19% respectively). In our study septic patients with preexisting AF had at least a twice-as-high rate of an-

### Table 2. Duration, treatment and clinical outcome of new onset (Group 1) and recurrent (Group 2) episodes of atrial fibrillation during the ICU stay of both study groups

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n = 37)</th>
<th>Group 2 (n = 44)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>«ICU arrhythmia day»</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(day, mean ± SD)</td>
<td>5.4 ± 7.7</td>
<td>3.2 ± 4.5</td>
<td>0.22</td>
</tr>
<tr>
<td>Duration of arrhythmia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(day, mean ± SD)</td>
<td>7.4 ± 6.1</td>
<td>11.07 ± 8.7</td>
<td>0.013</td>
</tr>
<tr>
<td>New CVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>1/37 (1%)</td>
<td>0/44</td>
<td>NS</td>
</tr>
<tr>
<td>New PE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>0/37</td>
<td>1/44 (1%)</td>
<td>NS</td>
</tr>
<tr>
<td>Antiarrhythmic therapy during hospital stay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>after ICU discharge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>8/32 (25%)</td>
<td>16/38 (42.1%)</td>
<td>0.02</td>
</tr>
<tr>
<td>Antiarrhythmic therapy at home after hospital discharge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>4/32 (12.5%)</td>
<td>13/38 (34.2%)</td>
<td>0.04</td>
</tr>
<tr>
<td>Proarrhythmic therapy during ICU stay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>24/37 (64.8%)</td>
<td>23/44 (52.2%)</td>
<td>NS</td>
</tr>
<tr>
<td>Anticoagulation therapy during hospital stay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>1/32 (3.1%)</td>
<td>5/38 (13.1%)</td>
<td>0.025</td>
</tr>
<tr>
<td>Anticoagulation therapy at home (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n, %)</td>
<td>2/32 (6.25%)</td>
<td>6/38 (15.7%)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

*from percent of patients who has been discharged at home with antiarrhythmic therapy recommendations; Anticoagulation therapy (as a preventive treatment for potential risk of new CVA and PE events) included during hospital stay Low Molecular Weight Heparin (LMWH) and warfarin at home; Proarrhythmic therapy included use of inotropic (dopamine, dobutamine, epinephrine) and vasopressors (norepinephrine) agents; Antiarrhythmic therapy during ICU stay included amiodarone and beta-blocker group; antiarrhythmic therapy at home included both beta-blocker and calcium-channel blockers group. NS — non significant, other abbreviations explained in text.
and recurrent episode of atrial fibrillation within the ICU stay (mean ± SD or median (IQR)

prevention of new stroke/PE episodes at home.

ity and mortality after new episodes of AF during the ICU

warranted for a precise clinical analysis of patients’ morbid-

be argued that a large prospective, multicenter study is

our conclusions regarding patients’ clinical outcome. It may

further limitation of our study, which significantly restricts

after discharge from the hospital. The small sample size is

of our study is the request for long-term clinical follow up

sible selection bias in both study groups. Another limitation

renal failure etc.).

risk of bleeding, coagulopathy, recurrent surgery, chronic

risk of potential complications and contraindications (high

during their hospital stay and at home because of a high

septic patients with new AF episodes.

antiarrhythmic and anticoagulation therapy of critically ill

the long-term therapeutic management requirements of

patients who had no previous past medical history of any

cardiac arrhythmias. We propose that a large multicenter

prospective study would help clarify clinical outcomes and

clinical outcomes and, associated costs of care. Crit Care Med 2001;

10.1016/j.ahj.2013.03.020.


ACKNOWLEDGEMENTS

1. The authors declare no financial disclosure.

2. The authors declare no conflict of interest.

References:


3. Angus DC, Linde-Zwirble WT, Lidicker J et al.: Epidemiology

of severe sepsis in the United States: analysis of incidence, outcome, and


4. Rudiger A, Singer M: Mechanisms of sepsis-induced cardiac
dysfunction, Crit Care Med 2007; 35: 1599−1608.

5. Muller-Werdan U, Buerek M, Ebelt H et al.: Septic cardiomyopa-


13. Ahmad S, Ramsay T, Huebsch L et al.: Continuous multi-

pone.0006642.


CONCLUSION

In the present study we demonstrated no difference in morbidity and mortality rates in ICU and after discharge between septic patients who had previous AF episodes and patients who had no previous past medical history of any cardiac arrhythmias. We propose that a large multicenter prospective study would help clarify clinical outcomes and the long-term therapeutic management requirements of antiarrhythmic and anticoagulation therapy of critically ill septic patients with new AF episodes.

Table 3. Laboratory dataa of study group of patients during the new and recurrent episode of atrial fibrillation within the ICU stay (mean ± SD or median (IQR)

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n = 37)</th>
<th>Group 2 (n = 44)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphorus blood level (mmol L⁻¹)</td>
<td>4.1 ± 1.52</td>
<td>3.5 ± 1.01</td>
<td>0.11</td>
</tr>
<tr>
<td>Serum calcium serum (mmol L⁻¹)</td>
<td>1.02 ± 0.1</td>
<td>1.06 ± 0.09</td>
<td>0.053</td>
</tr>
<tr>
<td>Serum magnesium (mmol L⁻¹)</td>
<td>2.2 ± 0.3</td>
<td>2.1 ± 0.45</td>
<td>0.38</td>
</tr>
<tr>
<td>Serum potassium (mEq L⁻¹)</td>
<td>4.02 ± 0.67</td>
<td>4.07 ± 0.54</td>
<td>0.67</td>
</tr>
<tr>
<td>Serum glucose (mg dL⁻¹)</td>
<td>161.3 ± 88.1</td>
<td>151.8 ± 7.3</td>
<td>0.54</td>
</tr>
<tr>
<td>Serum creatinine (mg dL⁻¹)</td>
<td>1.62 ± 1.03</td>
<td>1.23 ± 0.91</td>
<td>0.07</td>
</tr>
<tr>
<td>Serum urea (mg dL⁻¹)</td>
<td>90.08 ± 47.1</td>
<td>73.2 ± 39.5</td>
<td>0.08</td>
</tr>
<tr>
<td>pH arterial blood (g dL⁻¹)</td>
<td>7.32 ± 0.1</td>
<td>7.3 ± 0.1</td>
<td>0.53</td>
</tr>
<tr>
<td>Haemoglobin (g dL⁻¹)</td>
<td>9.9 ± 2.1</td>
<td>9.6 ± 1.9</td>
<td>0.5</td>
</tr>
<tr>
<td>WBC (G L⁻¹)</td>
<td>13 (2−37)</td>
<td>11 (2−59)</td>
<td>0.75</td>
</tr>
<tr>
<td>GL (G L⁻¹)</td>
<td>188,8 ± 83,4</td>
<td>225,1 ± 191,0</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*aAll laboratory data was collected during the new AF episode within the ICU stay. Note: no significant electrolyte disturbances were found in both study groups during the AF episode.

Corresponding author:
Evgeni Brotfain, MD
Department of Anesthesiology and Critical Care
Soroka Medical Center
Ben Gurion University of the Negev
Beer Sheva, Israel
e-mail: bem1975@gmail.com

Received: 6.12.2014
Accepted: 2.04.2015